Similarly, data from ExteNET published in 2017 demonstrated that 1 year of neratinib with chemotherapy and trastuzumab in the (post-neo)adjuvant setting reduced the number of clinically relevant BC recurrences in patients with HER2+ eBC [23]. Here, ERBB2 is linked to breast cancer.